Cargando…
Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone
PURPOSE: Tumor microRNAs (miRNAs) are released to biofluids directly or indirectly. Although urinary miRNAs are promising non-invasive biomarkers for the diagnosis of prostate cancer (PCa), their clinical application is challenging for technical reasons. We examined the efficacy of urinary hsv2-miR-...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Urological Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902421/ https://www.ncbi.nlm.nih.gov/pubmed/35244999 http://dx.doi.org/10.4111/icu.20210493 |
_version_ | 1784664597220818944 |
---|---|
author | Kang, Ho Won Byun, Young Joon Moon, Sung Min Kim, Kyeong Piao, Xuan-Mei Zheng, Chuang-Ming Moon, Sung-Kwon Choi, Yung Hyun Kim, Won Tae Kim, Yong-June Lee, Sang-Cheol Yun, Seok Joong Kim, Wun-Jae |
author_facet | Kang, Ho Won Byun, Young Joon Moon, Sung Min Kim, Kyeong Piao, Xuan-Mei Zheng, Chuang-Ming Moon, Sung-Kwon Choi, Yung Hyun Kim, Won Tae Kim, Yong-June Lee, Sang-Cheol Yun, Seok Joong Kim, Wun-Jae |
author_sort | Kang, Ho Won |
collection | PubMed |
description | PURPOSE: Tumor microRNAs (miRNAs) are released to biofluids directly or indirectly. Although urinary miRNAs are promising non-invasive biomarkers for the diagnosis of prostate cancer (PCa), their clinical application is challenging for technical reasons. We examined the efficacy of urinary hsv2-miR-H9 to hsa-miR-3659 ratio as a non-invasive diagnostic biomarker of PCa. MATERIALS AND METHODS: The expression of urinary miRNAs was quantified by real-time PCR in 116 samples from 53 patients with benign prostatic hyperplasia (BPH) and 63 patients with PCa. The miRNA expression ratio was calculated using an upregulated miRNA (hsv2-miR-H9) as the numerator and a downregulated miRNA (hsa-miR-3659) as the denominator. RESULTS: The urinary miR-H9 to miR-3659 ratio was significantly higher in PCa than in BPH controls (p<0.001). The diagnostic accuracy of the urinary miRNA expression ratio was comparable with that of prostate-specific antigen (PSA) (receiver operating characteristic [ROC] curve comparison, p=0.287). The area under the curve for urinary miRNA expression ratio was 0.862 and that for PSA was 0.642 in the “PSA gray zone” (3–10 ng/mL) (ROC curve comparison, p=0.034). The use of the urinary miRNA expression ratio would have prevented 70.6% of unnecessary prostate biopsies; however, 28.6% of PCa cases could be missed in patients within the PSA gray zone. CONCLUSIONS: The expression ratio of urinary miR-H9 to miR-3659 could be a relevant non-invasive biomarker for PCa diagnosis, particularly for patients within the PSA gray zone. |
format | Online Article Text |
id | pubmed-8902421 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Korean Urological Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-89024212022-03-16 Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone Kang, Ho Won Byun, Young Joon Moon, Sung Min Kim, Kyeong Piao, Xuan-Mei Zheng, Chuang-Ming Moon, Sung-Kwon Choi, Yung Hyun Kim, Won Tae Kim, Yong-June Lee, Sang-Cheol Yun, Seok Joong Kim, Wun-Jae Investig Clin Urol Original Article PURPOSE: Tumor microRNAs (miRNAs) are released to biofluids directly or indirectly. Although urinary miRNAs are promising non-invasive biomarkers for the diagnosis of prostate cancer (PCa), their clinical application is challenging for technical reasons. We examined the efficacy of urinary hsv2-miR-H9 to hsa-miR-3659 ratio as a non-invasive diagnostic biomarker of PCa. MATERIALS AND METHODS: The expression of urinary miRNAs was quantified by real-time PCR in 116 samples from 53 patients with benign prostatic hyperplasia (BPH) and 63 patients with PCa. The miRNA expression ratio was calculated using an upregulated miRNA (hsv2-miR-H9) as the numerator and a downregulated miRNA (hsa-miR-3659) as the denominator. RESULTS: The urinary miR-H9 to miR-3659 ratio was significantly higher in PCa than in BPH controls (p<0.001). The diagnostic accuracy of the urinary miRNA expression ratio was comparable with that of prostate-specific antigen (PSA) (receiver operating characteristic [ROC] curve comparison, p=0.287). The area under the curve for urinary miRNA expression ratio was 0.862 and that for PSA was 0.642 in the “PSA gray zone” (3–10 ng/mL) (ROC curve comparison, p=0.034). The use of the urinary miRNA expression ratio would have prevented 70.6% of unnecessary prostate biopsies; however, 28.6% of PCa cases could be missed in patients within the PSA gray zone. CONCLUSIONS: The expression ratio of urinary miR-H9 to miR-3659 could be a relevant non-invasive biomarker for PCa diagnosis, particularly for patients within the PSA gray zone. The Korean Urological Association 2022-03 2022-02-24 /pmc/articles/PMC8902421/ /pubmed/35244999 http://dx.doi.org/10.4111/icu.20210493 Text en © The Korean Urological Association https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Kang, Ho Won Byun, Young Joon Moon, Sung Min Kim, Kyeong Piao, Xuan-Mei Zheng, Chuang-Ming Moon, Sung-Kwon Choi, Yung Hyun Kim, Won Tae Kim, Yong-June Lee, Sang-Cheol Yun, Seok Joong Kim, Wun-Jae Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone |
title | Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone |
title_full | Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone |
title_fullStr | Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone |
title_full_unstemmed | Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone |
title_short | Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone |
title_sort | urinary hsv2-mir-h9 to hsa-mir-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902421/ https://www.ncbi.nlm.nih.gov/pubmed/35244999 http://dx.doi.org/10.4111/icu.20210493 |
work_keys_str_mv | AT kanghowon urinaryhsv2mirh9tohsamir3659ratioisaneffectivemarkerfordiscriminatingprostatecancerfrombenignprostatehyperplasiainpatientswithintheprostatespecificantigengreyzone AT byunyoungjoon urinaryhsv2mirh9tohsamir3659ratioisaneffectivemarkerfordiscriminatingprostatecancerfrombenignprostatehyperplasiainpatientswithintheprostatespecificantigengreyzone AT moonsungmin urinaryhsv2mirh9tohsamir3659ratioisaneffectivemarkerfordiscriminatingprostatecancerfrombenignprostatehyperplasiainpatientswithintheprostatespecificantigengreyzone AT kimkyeong urinaryhsv2mirh9tohsamir3659ratioisaneffectivemarkerfordiscriminatingprostatecancerfrombenignprostatehyperplasiainpatientswithintheprostatespecificantigengreyzone AT piaoxuanmei urinaryhsv2mirh9tohsamir3659ratioisaneffectivemarkerfordiscriminatingprostatecancerfrombenignprostatehyperplasiainpatientswithintheprostatespecificantigengreyzone AT zhengchuangming urinaryhsv2mirh9tohsamir3659ratioisaneffectivemarkerfordiscriminatingprostatecancerfrombenignprostatehyperplasiainpatientswithintheprostatespecificantigengreyzone AT moonsungkwon urinaryhsv2mirh9tohsamir3659ratioisaneffectivemarkerfordiscriminatingprostatecancerfrombenignprostatehyperplasiainpatientswithintheprostatespecificantigengreyzone AT choiyunghyun urinaryhsv2mirh9tohsamir3659ratioisaneffectivemarkerfordiscriminatingprostatecancerfrombenignprostatehyperplasiainpatientswithintheprostatespecificantigengreyzone AT kimwontae urinaryhsv2mirh9tohsamir3659ratioisaneffectivemarkerfordiscriminatingprostatecancerfrombenignprostatehyperplasiainpatientswithintheprostatespecificantigengreyzone AT kimyongjune urinaryhsv2mirh9tohsamir3659ratioisaneffectivemarkerfordiscriminatingprostatecancerfrombenignprostatehyperplasiainpatientswithintheprostatespecificantigengreyzone AT leesangcheol urinaryhsv2mirh9tohsamir3659ratioisaneffectivemarkerfordiscriminatingprostatecancerfrombenignprostatehyperplasiainpatientswithintheprostatespecificantigengreyzone AT yunseokjoong urinaryhsv2mirh9tohsamir3659ratioisaneffectivemarkerfordiscriminatingprostatecancerfrombenignprostatehyperplasiainpatientswithintheprostatespecificantigengreyzone AT kimwunjae urinaryhsv2mirh9tohsamir3659ratioisaneffectivemarkerfordiscriminatingprostatecancerfrombenignprostatehyperplasiainpatientswithintheprostatespecificantigengreyzone |